Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK forms collaboration with Angiochem around lysosomal storage disorders

Executive Summary

Angiochem Inc. (drug candidates capable of crossing the blood-brain barrier) has agreed to generate and develop for GlaxoSmithKline PLC an enzyme replacement therapy for an unspecified lysosomal storage disorder (LSD). GSK may expand the agreement to other LSDs, a group of rare inherited metabolic diseases caused by enzyme deficiencies that lead to build-up of toxic materials in the cells.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies